J P Bae1, M J Lage2, D Mo3, D R Nelson4, B J Hoogwerf5. 1. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285. Electronic address: bae_jay@lilly.com. 2. Managing Member, HealthMetrics Outcomes Research, 27576 River Reach Drive, Bonita Springs FL 34134. Electronic address: elagemj@hlthmetrics.com. 3. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285. Electronic address: mo_daojun@lilly.com. 4. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285. Electronic address: nelson_david_r@lilly.com. 5. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285. Electronic address: hoogwerf_byron_james@lilly.com.
Abstract
AIMS: Examine the association between obesity and glycemic control among patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM). METHODS: Data from US physician electronic health records (Humedica®) from 2009-2011 were utilized. Patients were defined as having above-target glycemic control if they had an HbA1c ≥7% at any time during the study period. Multinomial logistic regressions were conducted separately for T1DM and T2DM patients, and examined associations between BMI categories and probability of having above-target glycemic control (≥7% and <8%, ≥8% and <9%, or ≥9%) while controlling for patient demographics, general health, comorbid conditions, and antihyperglycemic medication use. RESULTS: There were 14,028 T1DM and 248,567 T2DM patients; 47.8% of T1DM and 63.4% of T2DM were obese (BMI ≥30kg/m(2)). For T1DM, being overweight (BMI 25-<30), obese class I (30-<35), II (35-<40), or III (≥40) was associated with a significantly higher probability of having HbA1c≥8% and <9% or ≥9%, while being overweight was associated with a significantly higher probability of having HbA1c ≥7% and <8% compared to normal BMI (BMI≥18.5 and<25). For T2DM patients, being overweight, obese class I, II, or III was associated with a significantly higher probability of having HbA1c ≥7% and <8%, ≥8% and <9%, or ≥9%. CONCLUSIONS: For both T1DM and T2DM patients, there were positive and statistically significant associations between being overweight or obese and having suboptimal glycemic control. These findings quantify the associations between obesity and glycemic control, and highlight the potential importance of individual characteristics on glycemic control.
AIMS: Examine the association between obesity and glycemic control among patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM). METHODS: Data from US physician electronic health records (Humedica®) from 2009-2011 were utilized. Patients were defined as having above-target glycemic control if they had an HbA1c ≥7% at any time during the study period. Multinomial logistic regressions were conducted separately for T1DM and T2DM patients, and examined associations between BMI categories and probability of having above-target glycemic control (≥7% and <8%, ≥8% and <9%, or ≥9%) while controlling for patient demographics, general health, comorbid conditions, and antihyperglycemic medication use. RESULTS: There were 14,028 T1DM and 248,567 T2DM patients; 47.8% of T1DM and 63.4% of T2DM were obese (BMI ≥30kg/m(2)). For T1DM, being overweight (BMI 25-<30), obese class I (30-<35), II (35-<40), or III (≥40) was associated with a significantly higher probability of having HbA1c≥8% and <9% or ≥9%, while being overweight was associated with a significantly higher probability of having HbA1c ≥7% and <8% compared to normal BMI (BMI≥18.5 and<25). For T2DM patients, being overweight, obese class I, II, or III was associated with a significantly higher probability of having HbA1c ≥7% and <8%, ≥8% and <9%, or ≥9%. CONCLUSIONS: For both T1DM and T2DM patients, there were positive and statistically significant associations between being overweight or obese and having suboptimal glycemic control. These findings quantify the associations between obesity and glycemic control, and highlight the potential importance of individual characteristics on glycemic control.
Authors: Stephanie L Fitzpatrick; Dea Papajorgji-Taylor; Jennifer L Schneider; Nangel Lindberg; Melanie Francisco; Ning Smith; Katie Vaughn; Elizabeth A Vrany; Felicia Hill-Briggs Journal: Transl Behav Med Date: 2022-07-18 Impact factor: 3.626
Authors: Mackenzie R Wehner; Robert Micheletti; Megan H Noe; Eleni Linos; David J Margolis; Haley B Naik Journal: J Am Acad Dermatol Date: 2019-12-20 Impact factor: 11.527
Authors: Agustin Lara-Esqueda; Sergio A Zaizar-Fregoso; Violeta M Madrigal-Perez; Mario Ramirez-Flores; Daniel A Montes-Galindo; Margarita L Martinez-Fierro; Iram P Rodriguez-Sanchez; José Guzman-Esquivel; Carmen Meza-Robles; Gabriel Ceja-Espiritu; Pablo A Kuri-Morales; Josuel Delgado-Enciso; Armando Barriguete-Melendez; Hector R Galvan-Salazar; Carlos E Barajas-Saucedo; Elvin Guillermo-Espinosa; Agustin D Lara-Basulto; Jesus F Gonzalez-Roldan; Ivan Delgado-Enciso Journal: J Diabetes Res Date: 2021-08-14 Impact factor: 4.011
Authors: Ahmed Chetoui; Kamal Kaoutar; Soufiane Elmoussaoui; Kaltoum Boutahar; Abdesslam El Kardoudi; Fatiha Chigr; Mohamed Najimi Journal: Int Health Date: 2020-01-20 Impact factor: 3.131